Relevance of KIR gene matching in unrelated hematopoietic stem cell transplantations

Tissue Antigens

Volumn 69, Issue SUPPL. 1, 2007, Pages 118-122

  Gagne, K ^a   Busson, M ^b   Balere Appert, M L ^c   Absi, L ^a   Jollet, I ^a   Bignon, J D ^a   Bois, M ^a   Dormoy, A ^a   Dubois, V ^a   Gebuhrer, L ^a   Loiseau, P ^d   Masson, D ^a   Moine, A ^a   Perrier, P ^e   Reviron, D ^a   Charron, D ^b,d   Raffoux, C ^c  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

^b INSERM   (France)

^c France Greffe de Moelle   (France)

^d HLA Laboratory   (France)

^e UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Graft vs host disease; Killer cell immunoglobulin like receptor; KIR gene matching; Survival; Unrelated hematopoietic stem cell transplantation

Indexed keywords

KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; CONFERENCE PAPER; CONTROLLED STUDY; DONOR; FEMALE; GENETIC ANALYSIS; GRAFT RECIPIENT; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HUMAN; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UNIVARIATE ANALYSIS;

ACUTE DISEASE; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; KILLER CELLS, NATURAL; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, IMMUNOLOGIC; SURVIVAL RATE; TISSUE DONORS;

EID: 34247261176     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2006.76210.x     Document Type: Conference Paper

References (27)

1. Hallett WH, Murphy WJ. Natural killer cells: biology and clinical use in cancer therapy. Cell Mol Immunol 2004: 1: 12-21.
2. Parham P. Immunogenetics of killer cell immunoglobulin-like receptors. Mol Immunol 2005: 42: 459-62.
3. Ruggeri L, Capanni M, Mancusi A, Martelli MF, Velardi A. The impact of donor natural killer cell alloreactivity on allogeneic hematopoietic transplantation. Transpl Immunol 2005: 14: 203-6.
4. Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002: 295: 2097-100.
5. Gagne K, Brizard G, Gueglio B et al. Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Hum Immunol 2002: 63: 271-80.
6. Davies SM, Ruggeri L, DeFor T et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 2002: 100: 3825-7.
7. Giebel S, Locatelli F, Lamparelli T et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003: 102: 814-9.
8. Bornhauser M, Schwerdtfeger R, Martin H, Frank KH, Theuser C, Ehninger G. Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood 2004: 103: 2860-1.
9. Bishara A, De Santis D, Witt CC et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens 2004: 63: 204-11.
10. Cook MA, Milligan DW, Fegan CD et al. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood 2004: 103: 1521-6.
11. Schaffer M, Malmberg KJ, Ringden O, Ljunggren HG, Remberger M. Increased infection-related mortality in KIR-ligand-mismatched unrelated allogeneic hematopoietic stem-cell transplantation. Transplantation 2004: 78: 1081-5.
12. Beelen DW, Ottinger HD, Ferencik S et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 2005: 105: 2594-600.
13. Hsu KC, Keever-Taylor CA, Wilton A et al. Improved outcome in HLA-identical sibling hematopoietic stem cell transplantation for acute myelogenous leukemia (AML) predicted by KIR and HLA genotypes. Blood 2005: 105: 4878-84.
14. De Santis D, Bishara A, Witt CS et al. Natural killer cell HLA-C epitopes and killer cell immunoglobulin-like receptors both influence outcome of mismatched unrelated donor bone marrow transplants. Tissue Antigens 2005: 65: 519-28.
15. Elmaagacli AH, Ottinger H, Koldehoff M et al. Reduced risk for molecular disease in patients with chronic myeloid leukemia after transplantation from a KIR-mismatched donor. Transplantation 2005: 79: 1741-7.
16. Verheyden S, Schots R, Duquet W, Demanet C. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia 2005: 19: 1446-51.
17. Sun JY, Gaidulis L, Dagis A et al. Killer Ig-like receptor (KIR) compatibility plays a role in the prevalence of acute GVHD in unrelated hematopoietic cell transplants for AML. Bone Marrow Transplant 2005: 56: 525-30.
18. Giebel S, Nowak I, Wojnar J et al. Impact of Activating Killer Immunoglobulin-like Receptor Genotype on Outcome of Unrelated Donor-Hematopoietic Cell Transplantation. Transplant Proc 2006: 38: 287-91.
19. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988: 16: 1215.
20. Gomez-Lozano N, Vilches C. Genotyping of human killer-cell immunoglobulin-like receptor genes by polymerase chain reaction with sequence-specific primers: an update. Tissue Antigens 2002: 59: 184-93.
21. Hsu KC, Liu XR, Selvakumar A, Mickelson E, O'Reilly RJ, Dupont B. Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets. J Immunol 2002: 169: 5118-29.
22. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974: 18: 295-304.
23. Przepiorka D, Weisdorf D, Martin P et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995: 15: 825-8.
24. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999: 94: 496-509.
25. Bignon JD, Gagne K. KIR matching in hematopoietic stem cell transplantation. Curr Opin Immunol 2005: 17: 553-9.
26. Leung W, Iyengar R, Turner V et al. R. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004: 172: 644-50.
27. Gardiner CM, Guethlein LA, Shilling HG et al. Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism. J Immunol 2001: 166: 2992-3001.